

Trimbow® (beclometasone/formoterol/glycopyrronium) Asthma Search Tool Rationale

This document explains the search rationale used to identify adult patients with asthma potentially eligible for Trimbow®.

This promotional search tool has been fully funded by Chiesi Ltd and developed by Oberoi Consulting Ltd.

Chiesi is providing this search tool to support clinicians in identifying adult asthma patients potentially eligible for Trimbow® (beclometasone/formoterol/glycopyrronium) [BDP/FF/G]. The search tool does not replace clinical judgement. It is the role of the healthcare organisation to assess the list of patients generated by the searches, to clinically review the patients identified and optimise their medication accordingly. Please note that Trimbow® may not be appropriate for all patients identified by this tool. Patient cohorts have been broken down by severe exacerbations (oral corticosteroid issues as a surrogate marker) and/or ACT to indicate symptom burden and reduced FEV1 to indicate impaired lung function. This approach supports the identification of patients who may have a higher risk disease profile. Please note Trimbow® is indicated for the maintenance treatment of asthma, in adults not adequately controlled with medium or high dose ICS/LABA (please see full licensed indication).

Trimbow® Licensing Information

Trimbow® pMDI 87/5/9: Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Trimbow® pMDI 172/5/9: Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Trimbow® Prescribing Information can be found via this link <https://www.chiesi.co.uk/hcp/prescribing-information-2/#trimbow>

Fostair® (beclometasone/formoterol) Prescribing Information can be found here: <https://www.chiesi.co.uk/hcp/prescribing-information-2/#fostair>

Clenil® (beclometasone) Prescribing information can be found here: <https://www.chiesi.co.uk/hcp/prescribing-information-2/#clenil>

Adverse events should be reported. Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk> or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.



Patient Cohorts

Cohort 1 - Adult asthma patients on moderate-strength ICS/LABA*

Identification focus:


Adult patients with asthma, prescribed **moderate-strength** ICS plus LABA (combination inhaler or separate ICS and LABA inhalers), who continue to experience symptoms, exacerbations, or demonstrate poor disease control.

Clinical opportunity:

Assessment for potential step-up to Trimbow® 87/5/9 where appropriate.

Rationale:

Help optimise symptom control, reduce exacerbation risk, align with evidence-based escalation pathways and simplify treatment where possible¹.



ICS: Inhaled corticosteroids; LABA: Long-acting β₂-agonist; OCS: Oral corticosteroids; ACT: Asthma Control Test; FEV₁: Forced Expiratory Volume in 1 second

*Prescription issued in last 4 months ** OCS is used as a proxy for exacerbation events (prescription issued in last 12 months)

1. Virchow et al., 2019, Lancet, 394:1737–1749. Available at: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(19\)32215-9/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32215-9/abstract) [Last accessed April 2026]

Patient Cohorts

Cohort 2 - Adult asthma patients on high-strength ICS/LABA*

Identification focus:


Adult patients with asthma, prescribed **high-strength** ICS plus LABA (combination inhaler or separate ICS and LABA inhalers), who continue to experience symptoms, exacerbations, or demonstrate poor disease control.

Clinical opportunity:

Assessment for potential step-up to Trimbrow® 172/5/9 where appropriate.

Rationale:

Help optimise symptom control, reduce exacerbation risk, align with evidence-based escalation pathways and simplify treatment where possible¹.



ICS: Inhaled corticosteroids; LABA: Long-acting β₂-agonist; OCS: Oral corticosteroids; ACT: Asthma Control Test; FEV₁: Forced Expiratory Volume in 1 second

*Prescription issued in last 4 months ** OCS is used as a proxy for exacerbation events (prescription issued in last 12 months)

1. Virchow et al., 2019, Lancet, 394:1737–1749. Available at: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(19\)32215-9/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32215-9/abstract) [Last accessed April 2026]

Exclusion Criteria

Patients excluded from all cohorts:

- Patients on palliative care register in last days or weeks of life (red or amber)
- Patients already receiving triple therapy with any combined ICS/LABA/LAMA inhaler or ICS/LABA/LAMA in separate inhalers

Moderate-Strength ICS Inhalers Included in the Searches

Clinical system searches cannot identify doses of an ICS; inhaler strength is therefore used as a proxy.

A comprehensive list of all currently marketed inhalers that are included in the searches are listed below, this list has been verified using NICE/BTS/SIGN and Rightbreathe.^{1,2}

* Inhalers marked with a single asterisk can deliver low or moderate doses, depending on the number of puffs inhaled. Inhalers are selected by both brand and generic name.

** If an inhaler is licensed for both moderate-and high-strength doses but would require 8 puffs per day to achieve the high dose, the inhaler has been placed in the moderate-strength cohort, to reflect likely real-world practice.

Beclometasone

Easyhaler Beclometasone 200mcg (DPI)
Clenil Modulite (beclometasone) 200mcg (pMDI)
Kelhale 100mcg (pMDI)**
Qvar 100mcg Autohaler (pMDI)**
Qvar 100mcg Easi-Breathe (pMDI)**
Qvar 100mcg (pMDI)**
Soprobec 200mcg (pMDI)

Budesonide

Easyhaler Budesonide 200mcg (DPI)
Pulmicort 200mcg Turbohaler (DPI)
Budelin Novolizer 200mcg (DPI) + refill**

Ciclesonide

Alvesco 80mcg (pMDI)
Alvesco 160mcg (pMDI, 60 doses, 120 doses)

Fluticasone

Flixotide 125mcg Evohaler (pMDI)
Flixotide 250mcg Accuhaler (DPI)

Beclometasone/formoterol

Bibecfo 100mcg/6mcg (pMDI)*
Fostair (beclometasone/formoterol) 100mcg/6mcg (pMDI)*
Fostair NEXThaler (beclometasone/formoterol) 100mcg/6mcg (DPI)*
Luforbec 100mcg/6mcg (pMDI)*
Proxor 100mcg/6mcg (pMDI)*
Vivaire 100mcg/6mcg (pMDI)*

Vivaire discontinued, but stocks still available in 2026 so included in searches.

ICS: inhaled corticosteroid; NICE: National Institute for Health and Care Excellence; BTS: British Thoracic Society; SIGN: Scottish Intercollegiate Guidelines; mcg: micrograms; DPI: dry powder inhaler; pMDI: pressurised, metered-dose inhaler.

1. National Institute for Health and Care Excellence, British Thoracic Society & Scottish Intercollegiate Guidelines Network, 2025. Inhaled corticosteroid doses for the BTS, NICE and SIGN asthma guideline, 12 November 2025. Available at: <https://www.nice.org.uk/guidance/ng245/resources/inhaled-corticosteroid-doses-for-the-bts-nice-and-sign-asthma-guideline-pdf-13558148029> [Last Accessed: April 2026].

2. RightBreathe. Available at: <https://www.rightbreathe.com> [Last Accessed: April 2026].

Moderate-Strength ICS Inhalers Included in the Searches

Clinical system searches cannot identify doses of an ICS; inhaler strength is therefore used as a proxy.

A comprehensive list of all currently marketed inhalers that are included in the searches are listed below, this list has been verified using NICE/BTS/SIGN and Rightbreathe.^{1,2}

* Inhalers marked with a single asterisk can deliver low or moderate doses, depending on the number of puffs inhaled. Inhalers are selected by both brand and generic name.

Budesonide/formoterol

DuoResp Spiromax 160mcg/4.5mcg (DPI)*
Fobumix Easyhaler 160mcg/4.5mcg (DPI)*
Symbicort Turbohaler 200mcg/6mcg (DPI)*
Symbicort 200mcg/6mcg (pMDI)*
WockAIR 160mcg/4.5mcg (DPI)*

Mometasone

Asmanex 200mcg Twisthaler (DPI)
Asmanex 400mcg Twisthaler (DPI)

Fluticasone/salmeterol

AirFluSal 125mcg/25mcg (pMDI)
Aloflute 125mcg/25mcg (pMDI)
Avenor 125mcg/25mcg (pMDI)
Combisal 125mcg/25mcg (pMDI)
Fixkoh Airmaster 250mcg/50mcg (DPI)
Fusacomb Easyhaler 250mcg/50mcg (DPI)
Sereflo 125mcg/25mcg (pMDI)
Sereflo Ciphaler 250mcg/50mcg (DPI)
Seretide 125 Evohaler 125mcg/25mcg (pMDI)
Seretide 250 Accuhaler 250mcg/50mcg (DPI)
Sirdupla 125mcg/25mcg (pMDI)

Fluticasone/vilanterol

Relvar Ellipta 92mcg/22mcg (DPI)*

Fluticasone/formoterol

Flutiform 125mcg/5mcg (pMDI)

ICS: inhaled corticosteroid; NICE: National Institute for Health and Care Excellence; BTS: British Thoracic Society; SIGN: Scottish Intercollegiate Guidelines; mcg: micrograms; DPI: dry powder inhaler; pMDI: pressurised, metered-dose inhaler.

1. National Institute for Health and Care Excellence, British Thoracic Society & Scottish Intercollegiate Guidelines Network, 2025. Inhaled corticosteroid doses for the BTS, NICE and SIGN asthma guideline, 12 November 2025. Available at: <https://www.nice.org.uk/guidance/ng245/resources/inhaled-corticosteroid-doses-for-the-bts-nice-and-sign-asthma-guideline-pdf-13558148029> [Last Accessed: April 2026].

2. RightBreathe. Available at: <https://www.rightbreathe.com> [Last Accessed: April 2026].

High-Strength ICS Inhalers Included in the Searches

Clinical system searches cannot identify doses of an ICS; inhaler strength is therefore used as a proxy.

A comprehensive list of all currently marketed inhalers that are included in the searches are listed below, this list has been verified using NICE/BTS/SIGN and Rightbreathe.^{1,2}

*Inhalers marked with an asterisk can deliver moderate or high doses, depending on the number of puffs inhaled. Inhalers are selected by both brand and generic name.

Beclometasone

Clenil Modulite (beclometasone) 250mcg (pMDI)
Soprobec 250mcg (pMDI)

Budesonide

Budesonide Easyhaler 400mcg (DPI)
Pulmicort 400mcg Turbohaler (DPI)*
Pulmicort 0.5mg and 1mg Respules

Fluticasone

Flixotide 250mcg Evohaler (pMDI)
Flixotide 500mcg Accuhaler (DPI)

Fluticasone/formoterol

Flutiform 250mcg/10mcg (pMDI)

Beclometasone/formoterol

Bibecfo 200mcg/6mcg (pMDI)
Fostair (beclometasone/formoterol) 200mcg/6mcg (pMDI)
Fostair NEXThaler (beclometasone/formoterol) 200mcg/6mcg (DPI)
Luforbec 200mcg/6mcg (pMDI)
Proxor 200mcg/6mcg (pMDI)
Vivaire 200mcg/6mcg (pMDI)

Budesonide/formoterol

DuoResp Spiromax 320mcg/9mcg (DPI)*
Fobumix Easyhaler 320mcg/9mcg (DPI)*
Symbicort 400mcg/12mcg Turbohaler (DPI)*
WockAIR 320mcg/9mcg (DPI)*

Fluticasone/vilanterol

Relvar Ellipta 184mcg/22mcg (DPI)

Fluticasone/salmeterol

AirFluSal 250mcg/25mcg (pMDI)
AirFluSal Forspiro 500mcg/50mcg (DPI)
Aloflute 250mcg/25mcg (pMDI)
Avenor 250mcg/25mcg (pMDI)
Combisal 250mcg/25mcg (pMDI)
Fixkoh Airmaster 500mcg/50mcg (DPI)
Fusacomb Easyhaler 500mcg/50mcg (DPI)
Sereflo 250mcg/25mcg (pMDI)
Sereflo Ciphaler 500mcg/50mcg (DPI)
Seretide 250mcg Evohaler (pMDI)
Seretide 500mcg Accuhaler (DPI)
Sirdupla 250mcg/25mcg (pMDI)
Stalpex 500mcg/50mcg (DPI)

ICS: inhaled corticosteroid; NICE: National Institute for Health and Care Excellence; BTS: British Thoracic Society; SIGN: Scottish Intercollegiate Guidelines; mcg: micrograms; DPI: dry powder inhaler; pMDI: pressurised, metered-dose inhaler.

1. National Institute for Health and Care Excellence, British Thoracic Society & Scottish Intercollegiate Guidelines Network, 2025. Inhaled corticosteroid doses for the BTS, NICE and SIGN asthma guideline, 12 November 2025. Available at: <https://www.nice.org.uk/guidance/ng245/resources/inhaled-corticosteroid-doses-for-the-bts-nice-and-sign-asthma-guideline-pdf-13558148029> [Last Accessed: April 2026].

2. RightBreathe. Available at: <https://www.rightbreathe.com> [Last Accessed: April 2026].

Oral Corticosteroids

The oral corticosteroids listed below are included in the searches, if issued in the last 12 months.

Oral Corticosteroids

- Prednisolone
- Prednisone
- Dexamethasone

Key Differences in Search Construction

When building inhaler searches across clinical systems, the methodology differs due to how each system structures medication data.

EMIS Web

- The searches are built to identify only active prescription status
- Only prescriptions that are both active and issued within the last 4 months are included

SystemOne

- The searches are built using issue date
- Inhalers issued within the last 4 months will be included even if discontinued